Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Endometrial Cancer

Interventions

DRUG

Topotecan

1.4mg/㎡, orally administered, d1-5

DRUG

Toripalimab

240mg, intravenous drip, d1, q3w

Trial Locations (1)

Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06548763 - Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | Biotech Hunter | Biotech Hunter